Source comparison
Comparison: KPV Dosing Protocols in Colitis Models
DSS-Induced Colitis 1mg/day Subcutaneous Once daily 7–10 days 45–60% reduction in DAI score vs control Effective at moderate dose; plateau observed above 1mg TNBS-Induced Colitis 1.5mg/day 7–14 days 50–70% reduction in macroscopic damage score Requires higher
This comparison does not assign a generated winner or score.
- DSS-Induced Colitis
- 1mg/day
- Subcutaneous
- Once daily
- 7–10 days
- 45–60% reduction in DAI score vs control
- Effective at moderate dose; plateau observed above 1mg
- TNBS-Induced Colitis
- 1.5mg/day
- 7–14 days
- 50–70% reduction in macroscopic damage score
- Requires higher dose due to transmural inflammation; efficacy plateaus at 1.5mg
- Oral Enteric-Coated
- 8–10mg/day
- Oral
- Twice daily
- 14 days
- Only 8–12% bioavailability; inconsistent plasma levels
- Poor absorption makes oral route impractical for research
- Twice-Daily SC Protocol
- 0.5mg BID
- 10 days
- 10–15% incremental improvement vs QD dosing (not statistically significant)
- Marginal benefit; QD dosing sufficient for most applications